Kodiak Sciences (Kodiak Sciences) Cash-to-Debt : 3.50 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kodiak Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.50.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kodiak Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Kodiak Sciences's Cash-to-Debt or its related term are showing as below:

KOD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14 Med: 10.83 Max: No Debt
Current: 3.5

During the past 8 years, Kodiak Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.14. And the median was 10.83.

KOD's Cash-to-Debt is ranked worse than
59.91% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs KOD: 3.50

Kodiak Sciences Cash-to-Debt Historical Data

The historical data trend for Kodiak Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kodiak Sciences Cash-to-Debt Chart

Kodiak Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

173.89

12.52

9.14

5.46

3.50

Kodiak Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															5.46	4.86	4.47	4.14	3.50

Competitive Comparison of Kodiak Sciences's Cash-to-Debt

For the Biotechnology subindustry, Kodiak Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kodiak Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's Cash-to-Debt falls into.

Kodiak Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kodiak Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	285.507	/	(9.77	+	71.862)
	=	3.50

Kodiak Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	285.507	/	(9.77	+	71.862)
	=	3.50

Kodiak Sciences (NAS:KOD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kodiak Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences (Kodiak Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

K27:Germany

Address

1200 Page Mill Road, Palo Alto, CA, USA, 94304

Website

https://www.kodiak.com

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Executives

Jason Ehrlich	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
John A. Borgeson	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth	director, 10 percent owner, officer: Chairman, President and CEO	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang	officer: See Remarks	2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek	director	P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016